Here are five things to know:
1. These corrections dismissed two years of the company’s devices’ data.
2. Theranos reported it voided test results from 2014 and 2015.
3. In an email, company spokeswoman Brooke Buchanan wrote Theranos has taken “comprehensive corrective measures to address the issues CMS raised in their observations.”
4. The U.S. Securities and Exchange Commission, the U.S. Attorney’s Office in San Francisco and health regulators have investigated the efficacy of Theranos technology.
5. Theranos claims its technology can run many diagnostic tests with only a few drops of blood.
Recent articles:
Culbertson Outpatient Specialty Clinic adds general surgeon team — 4 key notes
Leveraging the Internet to your practice’s benefit — 6 medical marketing strategies from Dr. Tony Mork
7 things for ASC leaders to know for Thursday — May 19, 2016
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.